Alector Sees Unusually Large Options Volume (NASDAQ:ALEC)

Alector, Inc. (NASDAQ:ALEC) was the target of some unusual options trading on Tuesday. Stock traders purchased 20,569 put options on the company. This represents an increase of approximately 5,950% compared to the typical volume of 340 put options.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. UBS Group reiterated a “neutral” rating and issued a $1.50 target price on shares of Alector in a research note on Tuesday. Weiss Ratings raised shares of Alector from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Finally, Morgan Stanley increased their price objective on shares of Alector from $2.00 to $3.00 and gave the company an “underweight” rating in a research note on Tuesday. Three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $3.40.

Alector Trading Up 6.1%

Shares of Alector stock opened at $1.92 on Thursday. Alector has a 1 year low of $1.09 and a 1 year high of $3.40. The firm has a market cap of $214.39 million, a PE ratio of -1.75 and a beta of 0.62. The stock has a fifty day moving average price of $2.06 and a 200-day moving average price of $2.03. The company has a debt-to-equity ratio of 0.80, a current ratio of 5.26 and a quick ratio of 5.26.

Alector (NASDAQ:ALEC) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. The company had revenue of $3.32 million for the quarter, compared to the consensus estimate of $1.71 million. Alector had a negative net margin of 850.13% and a negative return on equity of 531.03%. Equities research analysts anticipate that Alector will post -0.87 EPS for the current year.

Key Stories Impacting Alector

Here are the key news stories impacting Alector this week:

• Positive Sentiment: Genentech licensed Alector’s AL050 program globally for Parkinson’s disease. The agreement includes a $100 million upfront payment and potential milestone payments of up to $1.27 billion, plus royalties. The deal could materially strengthen Alector’s cash position while transferring late-stage development and commercialization responsibilities to a large pharmaceutical partner. Alector inks global license deal with Genentech
• Positive Sentiment: The transaction is being viewed as a significant validation of Alector’s neurodegenerative-disease technology and attracted broader investor attention after reports highlighted the potential $1.27 billion deal value. The upfront payment is particularly important for a clinical-stage biotechnology company with substantial operating losses. Alector shares up after sealing $1.27bn Roche Parkinson’s disease license deal
• Positive Sentiment: Alector announced a virtual research and development event to discuss progress across its wholly owned Alector Brain Carrier pipeline, including AL137, an anti-amyloid beta antibody, AL164, a tau siRNA program, and AL062, an alpha-synuclein siRNA program. The presentation could provide additional clinical catalysts and visibility into the company’s remaining pipeline. Alector to Host Virtual Research and Development Event
• Neutral Sentiment: The potential $1.27 billion headline value is milestone-dependent rather than guaranteed, so the immediate financial benefit is primarily the $100 million upfront payment. Future value will depend on clinical results, regulatory progress, and Genentech’s development decisions. Genentech Commits $100 Million Upfront in Potential $1.27 Billion Parkinson’s Deal
• Negative Sentiment: Unusually heavy put-option activity was reported, with 20,569 puts purchased versus typical daily volume of about 340. This may signal bearish positioning or hedging and adds a cautionary indicator despite the positive licensing news.

Insider Transactions at Alector

In other Alector news, CFO Neil Berkley sold 29,251 shares of the business’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $2.66, for a total transaction of $77,807.66. Following the completion of the sale, the chief financial officer directly owned 350,649 shares of the company’s stock, valued at approximately $932,726.34. The trade was a 7.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Arnon Rosenthal sold 72,606 shares of the stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $2.66, for a total value of $193,131.96. Following the completion of the sale, the chief executive officer directly owned 2,294,600 shares of the company’s stock, valued at approximately $6,103,636. This trade represents a 3.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 111,303 shares of company stock valued at $295,633 in the last quarter. Company insiders own 8.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in shares of Alector in the 2nd quarter worth approximately $15,774,000. Nantahala Capital Management LLC bought a new position in Alector during the second quarter valued at $8,679,399. Foresite Capital Management IV LLC purchased a new stake in Alector in the fourth quarter worth $6,064,000. Merck & Co. Inc. purchased a new stake in Alector in the second quarter worth $7,126,896. Finally, 683 Capital Management LLC raised its stake in shares of Alector by 235.0% in the fourth quarter. 683 Capital Management LLC now owns 3,350,000 shares of the company’s stock valued at $5,226,000 after buying an additional 2,350,000 shares during the period. 85.83% of the stock is owned by institutional investors.

About Alector

Alector, Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s approach, known as immuno-neurology, seeks to use the immune system to protect brain health and address biological mechanisms involved in conditions such as Alzheimer’s disease, frontotemporal dementia and Parkinson’s disease.

Alector’s pipeline includes latozinemab, an antibody designed to increase levels of progranulin, a protein associated with the health and function of brain cells.